ZBIO (Zenas BioPharma) Other Income (Expense) : $7.33 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Other Income (Expense)?

Zenas BioPharma's other income expense for the Zenas BioPharma's pretax income for the three months ended in Dec. 2024 was $3.45 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was $7.33 Mil.

Zenas BioPharma Other Income (Expense) Historical Data

The historical data trend for Zenas BioPharma's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma Other Income (Expense) Chart

Zenas BioPharma Annual Data

Trend

Dec22

Dec23

Dec24

Other Income (Expense)

-44.08

-9.68

7.33

Zenas BioPharma Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Income (Expense)	Get a 7-Day Free Trial				0.49	-0.22	1.73	2.38	3.45

Zenas BioPharma Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.33 Mil.

Zenas BioPharma (NAS:ZBIO) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Zenas BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

852 Winter Street, Suite 250, Waltham, MA, USA, 02451

Website

https://www.zenasbio.com

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.